About REXAHN

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing the next generation of targeted therapeutics for the treatment of cancer.
Rexahn's clinical development programs target specific proteins that are selectively localized in human cancer cells and not in healthy tissues resulting in increased efficacy and reduced toxicity.


News

Rexahn Announces Poster Presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting


Rexahn Pharmaceuticals Reports First Quarter 2015 Financial Results and Pipeline Update


More


Portfolio